WO2001042467A3 - Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer - Google Patents

Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer Download PDF

Info

Publication number
WO2001042467A3
WO2001042467A3 PCT/US2000/033312 US0033312W WO0142467A3 WO 2001042467 A3 WO2001042467 A3 WO 2001042467A3 US 0033312 W US0033312 W US 0033312W WO 0142467 A3 WO0142467 A3 WO 0142467A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
kits
compositions
methods
cervical cancer
assessment
Prior art date
Application number
PCT/US2000/033312
Other languages
French (fr)
Other versions
WO2001042467A2 (en )
Inventor
Robert Schlegel
James Deeds
Allison Berger
Xumei Zhao
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57411Specifically defined cancers of cervix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Abstract

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers. A variety of novel markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of cervical cancer.
PCT/US2000/033312 1999-12-08 2000-12-08 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer WO2001042467A3 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US16968199 true 1999-12-08 1999-12-08
US60/169,681 1999-12-08
US17135099 true 1999-12-21 1999-12-21
US60/171,350 1999-12-21
US18931500 true 2000-03-14 2000-03-14
US60/189,315 2000-03-14
US20379100 true 2000-05-12 2000-05-12
US60/203,791 2000-05-12
US21060000 true 2000-06-09 2000-06-09
US60/210,600 2000-06-09
US22011400 true 2000-07-21 2000-07-21
US60/220,114 2000-07-21

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2074201A AU2074201A (en) 1999-12-08 2000-12-08 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Publications (2)

Publication Number Publication Date
WO2001042467A2 true WO2001042467A2 (en) 2001-06-14
WO2001042467A3 true true WO2001042467A3 (en) 2002-09-12

Family

ID=27558590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033312 WO2001042467A3 (en) 1999-12-08 2000-12-08 Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer

Country Status (1)

Country Link
WO (1) WO2001042467A3 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001059115A3 (en) * 2000-02-09 2002-01-24 Urogenesys Inc 83p5g4: a tissue specific protein highly expressed in prostate cancer
US20020102641A1 (en) * 2000-03-24 2002-08-01 Susan Schia Vi Oncogenic osteomalacia-related gene 1
US7034135B2 (en) 2000-05-03 2006-04-25 Millennium Pharmaceuticals, Inc. Molecules of the NBS/LRR protein family and uses thereof
US20020055626A1 (en) * 2000-06-09 2002-05-09 Turner C. Alexander Novel human seven transmembrane proteins and polynucleotides encoding the same
WO2002002759A3 (en) * 2000-06-29 2002-08-29 Rachel E Meyers A human alpha/beta hydrolase family member (32225) and uses thereof
WO2002020738A3 (en) * 2000-09-08 2002-06-20 Millennium Pharm Inc 27877, a phospholipase and uses therefor
US7119185B2 (en) * 2000-12-21 2006-10-10 Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
US20060063230A1 (en) 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002066623A3 (en) * 2001-02-21 2003-01-30 Bayer Ag Regulation of human phosphatidic acid-preferring phospholipase a1
WO2002081642A3 (en) * 2001-04-06 2003-11-20 Imran Ahmad Gene brcc-3 and diagnostic and therapeutic uses thereof
CA2442993C (en) 2001-04-10 2011-10-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7335467B2 (en) * 2001-05-15 2008-02-26 Ludwig Institute For Cancer Research Breast cancer antigens
US20030144225A1 (en) * 2001-12-28 2003-07-31 Karras James G. Antisense modulation of macrophage inflammatory protein 3-alpha expression
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
EP1565581B1 (en) * 2002-08-20 2011-08-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
CN103393672A (en) * 2003-02-12 2013-11-20 乔治敦大学 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
WO2004087957A3 (en) * 2003-04-03 2005-07-28 Oncomethylome Sciences S A Hypermethylated genes and cervical cancer
EP1692260A2 (en) * 2003-10-06 2006-08-23 Centocor, Inc. Hypoxia - responsive human cngh-0002 genes and polypeptides
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1819835B1 (en) 2004-12-08 2010-08-04 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005967A1 (en) * 1996-08-05 1998-02-12 Quantum Biosystems Ltd., In Creditors' Voluntary Liquidation, Acting By Its Liquidator, Roger William Gillett Of Crane & Partners Assessment of cervical cells
WO1998009170A2 (en) * 1996-08-30 1998-03-05 Matritech, Inc. Methods and compositions for the detection of cervical cancer
WO2001042792A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005967A1 (en) * 1996-08-05 1998-02-12 Quantum Biosystems Ltd., In Creditors' Voluntary Liquidation, Acting By Its Liquidator, Roger William Gillett Of Crane & Partners Assessment of cervical cells
WO1998009170A2 (en) * 1996-08-30 1998-03-05 Matritech, Inc. Methods and compositions for the detection of cervical cancer
WO2001042792A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_HTG EMBL; 30 August 1999 (1999-08-30), BIRREN, B. ET AL.: "Homo sapiens chromosome 15 clone RP11-16B9 map 15", XP002175250 *
DATABASE EM_HUM EMBL; 2 November 1999 (1999-11-02), HEILIG, R. ET AL.: "Human chromosome 14 DNA sequence BAC R-307P22 of library RPCI-11", XP002175251 *
NIELSEN H ET AL: "IDENTIFICATION OF PROKARYOTIC AND EUKARYOTIC SIGNAL PEPTIDES AND PREDICTION OF THEIR CLEAVAGE SITES", PROTEIN ENGINEERING, vol. 10, no. 1, 1997, pages 1 - 6, XP002072638, ISSN: 0269-2139 *

Also Published As

Publication number Publication date Type
WO2001042467A2 (en) 2001-06-14 application

Similar Documents

Publication Publication Date Title
WO2002010436A3 (en) Prognostic classification of breast cancer
WO2002024179A3 (en) Method for reducing toxicity of combined chemotherapies
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2004110245A3 (en) Combination therapy for cancer treatment
WO2002062763A3 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2004041115A3 (en) Novel human elastases and stress urinary incontinence
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
WO2004061423A3 (en) Compositions and methods for diagnosing and treating colon cancers
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2001082871A3 (en) Method of using zinc isotope for therapy and diagnosis of colon cancer

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP